Results 111 to 120 of about 53,085 (229)
Proteasome inhibition alleviates proteinuria in Lmx1b knock-in mice with dysfunctional LIM domains. [PDF]
Nat CommunHermens J, Lucke L, Pieles O, Maier O, Othmen H, Burghardt T, Schmidt A, Moser M, Madej MG, Schwartz U, Zaparty M, Witzgall R. +11 moreeuropepmc +1 more sourceSubcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study [PDF]
Arthur Bobin, Lisa Durocher, Cyrille Touzeau, Nicolas Branche, Aurore Perrot, Mamoun Dib, Jean‐Sébastien Blade, Thomas Chalopin, Lydia Montes, Julie Gay, Mourad Tiab, Margaret Macro, Titouan Cazaubiel, Frédérique Orisini Piocelle, Alberto Santagostino, Adrienne de Labarthe, Marlène Ochmann, Christophe Roul, Reza Tabrizi, Muriel Newinger-Porte, Olivier Fitoussi, Mony Morisse Chenda, Rick Zhang, Douaa Dhahri, Murielle Roussel, Lionel Karlin, Mohamad Mohty, Philippe Moreau, Anaïs Schavgoulidze, Jill Corre, Thierry T.F. Facon, Cyrille Hulin, Salomon Manier, Stéphanie Ragot, Xavier P Leleu +34 moreopenalex +1 more sourceA Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors. [PDF]
Cancer MedHo WL, Hsieh MY, Liao YM, Chiou SS, Shiah HS, Chiang CH, Jou ST, Yen HJ, Lee YY, Liang ML, Yeh TC, Chou YC, Huang FL, Chen SH, Lee HL, Kuo CC, Yang YS, Chen SM, Tsai ML, Chang H, Hsieh KL, Fang CL, Chang CY, Wang JL, Chen CC, Loh JK, Lin PC, Lin TC, Wang SC, Tu YF, Cheng CN, Chuang JM, Tran HM, Sung SY, Lai I, Wu KS, Miser JS, Liu YL, Wong TT. +38 moreeuropepmc +1 more sourceAdditional file 1 of Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke, Andreas Waha, Leif Oltedal, Judit Haász, Surendra Kumar, Even Birkeland, Frode Selheim, Stein Atle Lie, Martha Chekenya +10 moreopenalex +1 more sourceAdditional file 5 of Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke, Andreas Waha, Leif Oltedal, Judit Haász, Surendra Kumar, Even Birkeland, Frode Selheim, Stein Atle Lie, Martha Chekenya +10 moreopenalex +1 more sourceAdditional file 6 of Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke, Andreas Waha, Leif Oltedal, Judit Haász, Surendra Kumar, Even Birkeland, Frode Selheim, Stein Atle Lie, Martha Chekenya +10 moreopenalex +1 more sourceAdditional file 8 of Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke, Andreas Waha, Leif Oltedal, Judit Haász, Surendra Kumar, Even Birkeland, Frode Selheim, Stein Atle Lie, Martha Chekenya +10 moreopenalex +1 more source
